Understanding breast cancer stem cell heterogeneity: time to move on to a new research paradigm

BMC Medicine

Ferdinando Mannello¹ 

[1] Department of Biomolecular Sciences, Section of Clinical Biochemistry and Cell Biology, University ‘Carlo Bo’, Via O. Ubaldini 7, Urbino, PU, 61029, Italy

关键词: Stem cells;    Mammosphere;    Ep-CAM;    CD44/CD24/CD49f;    Cancer heterogeneity;    Breast cancer;    Biomarkers;   

Others  :  856954
DOI  :  10.1186/1741-7015-11-169

 received in 2013-06-27, accepted in 2013-06-28,  发布年份 2013

【 摘 要 】

Human breast cancer (BC) is one of the leading causes of death for women worldwide, and is characterized by a group of highly heterogeneous lesions. The morphological and biomolecular heterogeneity of BC cells, accompanied by dynamic plasticity of the BC microenvironment and the presence of stem-like cells, make tumor categorization an urgent and demanding task.

The major limitations in BC research include the high flexibility rate of breast cancer stem cells (BCSCs) and the difficulty of their identification. Improved profiling methods and extensive characterization of BCSCs were recently presented in BMC Cancer, highlighting that the majority of BC cells had a luminal EpCAM^high/CD49f⁺ phenotype, and identification of CD44^high/CD24^low subpopulation of cancer stem cells significantly improves the flow cytometry measurement of BCSCs with higher stem/progenitor ability.

Future developments in single-cell omics will potentially revolutionize cancer biology and clinical practice, providing better understanding of BC heterogeneity, how BCSCs evolve, and which BC cells to target to avoid drug resistance.

Please see related research published in BMC Cancer: http://www.biomedcentral.com/1471-2407/13/289/abstract webcite

【 授权许可】

   
2013 Mannello; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Hsiao YH, Chou MC, Fowler C, Mason JT, Man YG: Breast cancer heterogeneity: mechanisms, proofs, and implications. J Cancer 2010, 1:6-13.
• [2]Dawson SJ, Rueda OM, Aparicio S, Caldas C: A new genome-driven integrated classification of breast cancer and its implications. EMBO J 2013, 32:617-628.
• [3]Almendro V, Marusyk A, Polyak K: Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol 2013, 8:277-302.
• [4]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
• [5]Polyak K: Heterogeneity in breast cancer. J Clin Invest 2011, 121:3786-3788.
• [6]Place AE, Jin HS, Polyak K: The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res 2011, 13:227. BioMed Central Full Text
• [7]Mannello F, Medda V, Tonti GA: Protein profile analysis of the breast microenvironment to differentiate healthy women from breast cancer patients. Expert Rev Proteomics 2009, 6:43-60.
• [8]Higgins MJ, Baselga J: Targeted therapies for breast cancer. J Clin Invest 2011, 121:3797-3803.
• [9]Gangopadhyay S, Nandy A, Hor P, Mukhopadhyay A: Breast cancer stem cells: a novel therapeutic target. Clin Breast Cancer 2013, 13:7-15.
• [10]Ablett MP, Singh JK, Clarke RB: Stem cells in breast tumours: are they ready for the clinic? Eur J Cancer 2012, 48:2104-2116.
• [11]Valent P, Bonnet D, Wohrer S, Andreeff M, Copland M, Chomienne C, Eaves C: Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications. Cancer Res 2013, 73:1037-1045.
• [12]Polyak K, Vogt PK: Progress in breast cancer research. Proc Natl Acad Sci USA 2012, 109:2715-2717.
• [13]Virchow R: Die cellular pathologie in ihrer begründung auf physiologische und pathologische gewebelehre. Berlin: Von August Hirschwald; 1858.
• [14]Nowell PC: The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
• [15]Li Y, Laterra J: Cancer stem cells: distinct entities or dynamically regulated phenotypes? Cancer Res 2012, 72:576-580.
• [16]Vermeulen L, de Sousa EM, Richel DJ, Medema JP: The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol 2012, 13:e83-e89.
• [17]Tang DG: Understanding cancer stem cell heterogeneity and plasticity. Cell Res 2012, 22:457-472.
• [18]Medema JP: Cancer stem cells: the challenges ahead. Nat Cell Biol 2013, 15:338-344.
• [19]Al-Hajj M, Wicha MS, Ito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100:3983-3988.
• [20]Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al.: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
• [21]Ghebeh H, et al.: Profiling of normal and malignant breast tissues show CD44high/CD24low phenotype as a predominant stem/progenitor marker when used in combination with Ep-CAM/CD49f markers. BMC Cancer 2013, 13:289. BioMed Central Full Text
• [22]Valent P, Bonnet D, De MR, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, et al.: Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 2012, 12:767-775.
• [23]Mannello F, Ligi D, Magnani M: Deciphering the single-cell omic: innovative application for translational medicine. Expert Rev Proteomics 2012, 9:635-648.